Tech Company Financing Transactions
Starget Pharma Funding Round
Cancer Focus Fund participated in a $5.1 million venture round for Starget Pharma. The funding round closed on 10/28/2024.
Transaction Overview
Company Name
Announced On
10/28/2024
Transaction Type
Venture Equity
Amount
$5,100,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to conduct a Phase 1b clinical trial of its lead theranostic, DOTA-PTR-58.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Rehov Snir 26
Ramat HaSharon, 4704087
Israel
Ramat HaSharon, 4704087
Israel
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Starget Pharma is a peptide-based platform technology company founded in 2019. Starget is developing Smart Targeted Radioligands (STRs) for next-generation targeted cancer radiotherapy. Our leadership is a multi-disciplinary team with decades of experience in peptide drug discovery and development and business entrepreneurs to overcome the challenge of designing novel drug-like targeted radioligand for a broad range of cancer targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Ronen Kalmanson
Chief Executive Officer
Sigal Cusnir
VP - R & D
Mor Oron-Herman
Browse more venture capital transactions:
Prev: 10/28/2024: UnitPlus venture capital transaction
Next: 10/28/2024: Detectify venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs